Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR-Chip Makers Cardea Bio, Nanosens Agree to Merge

NEW YORK – Cardea Bio and Nanosens Innovations — the companies that teamed up to develop a CRISPR-Cas9-based biosensor diagnostic device using a graphene transistor called the CRISPR-Chip — announced today that they are merging.

Nanosens will become a subsidiary of Cardea, and the companies plan to sell CRISPR-Chip technology-based products under the Nanosens brand. Kiana Aran — an assistant professor and principal investigator at the Keck Graduate Institute of Applied Life Sciences, and cofounder of Nanosens — will join Cardea as chief science officer.

Financial terms of the deal weren't disclosed. The closing of the proposed merger is subject to stockholder approval and customary closing conditions.

The companies made a splash earlier this year when they announced they had developed a CRISPR-based diagnostic chip that could analyze DNA in its native state, without the need for amplification, labeling, or optical instruments. The graphene-based chips are able to quickly signal whether or not a specific mutation, protein, or other component is present, according to Cardea CEO Michael Heltzen.

Cardea is looking to develop a line of CRISPR-Chip-based products that would have uses as disease diagnostics, agricultural tools, and even research tools to validate the efficiency and specificity of other CRISPR-based technologies.

Concurrent with the merger announcement, Cardea also said it has launched an early-access program for its first CRISPR-Chip-based product under the Nanosens brand, the Genome Sensor. Users will be able to program the sensor with single guide RNAs in order to search unamplified genomes for diagnostic, research, or R&D purposes.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.